• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Immunol Res . The Impact of Killer Cell Immunoglobulin-Like Receptors and Human Leukocyte Antigen-E, Human Leukocyte Antigen-G Polymorphisms on I

tetano

Editor, Senior Moderator
J Immunol Res


. 2025 May 12:2025:6691437.
doi: 10.1155/jimr/6691437. eCollection 2025. The Impact of Killer Cell Immunoglobulin-Like Receptors and Human Leukocyte Antigen-E, Human Leukocyte Antigen-G Polymorphisms on Innate Immunity and COVID-19 Severity

Cigdem Kekik[SUP] 1 [/SUP], Sonay Temurhan[SUP] 1 [/SUP], Yeliz Ogret[SUP] 1 [/SUP], Behnoush Nasr Zanjani[SUP] 2 [/SUP], Demet Kıvanc[SUP] 1 [/SUP], Fatma Savran Oguz[SUP] 1 [/SUP], Murat Kose[SUP] 3 [/SUP], Fatma Betul Oktelik[SUP] 4 [/SUP], Gunnur Deniz[SUP] 4 [/SUP]



Affiliations
Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection spans a spectrum of symptoms, ranging from mild respiratory issues to severe outcomes like pneumonia, acute respiratory distress syndrome, and fatality. Natural killer (NK) cells, governed by killer cell immunoglobulin-like receptors (KIRs), play a pivotal role in directly combating viral infections. Emerging studies indicate a decline in NK cell numbers and heightened NKG2A expression in infected individuals. Objective: This study focuses on genotyping human leukocyte antigen (HLA)-E, HLA-G, and KIR in SARS-CoV-2-positive individuals, comparing data between those with mild and moderate/severe symptoms. The cohort comprised 100 COVID-19-positive patients and 100 healthy volunteers, both groups subjected to DNA isolation and genotyping using sequence-based sequencing. Results: In 97 COVID-19-positive patients (52 mild, 24 moderate, and 21 severe) and 100 healthy volunteers, the study revealed protective associations with inhibitory alleles (KIR2DL1, KIR2DL3, KIR2DL4, KIR3DL1, KIR3DL2, and pseudo-alleles like KIR3DP1 [SUP][/SUP] 003). Conversely, predisposing factors included activator alleles (KIR2DS2, KIR3DS1) and pseudo-alleles (KIR3DP [SUP][/SUP] 001/002). The G [SUP][/SUP] 01:04 allele and G [SUP][/SUP] 01:04-G [SUP][/SUP] 01:04 genotype emerged as protective, while the HLA-E [SUP][/SUP] 01:03-HLA-E [SUP][/SUP] 01:03 genotype may negatively impact disease prognosis. Conversely, the HLA-E [SUP][/SUP] 01:01-HLA-E [SUP][/SUP] 01:03 and HLA-E [SUP][/SUP] 01:01-HLA-E [SUP][/SUP] 01:01 genotypes may confer protection. Conclusion: Genetic variations in KIR, HLA-E, and HLA-G are associated with susceptibility and resistance to severe COVID-19 outcomes. This elucidates the intricate interplay of NK cells and immune-related genes, offering insights into potential therapeutic avenues and personalized approaches.

Keywords: COVID-19; HLA-G genotype; Human Leukocyte Antigen-E (HLA-E); killer cell immunoglobulin-like receptor (KIR); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

 
Back
Top Bottom